859 related articles for article (PubMed ID: 30895304)
1. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.
Trebeschi S; Drago SG; Birkbak NJ; Kurilova I; Cǎlin AM; Delli Pizzi A; Lalezari F; Lambregts DMJ; Rohaan MW; Parmar C; Rozeman EA; Hartemink KJ; Swanton C; Haanen JBAG; Blank CU; Smit EF; Beets-Tan RGH; Aerts HJWL
Ann Oncol; 2019 Jun; 30(6):998-1004. PubMed ID: 30895304
[TBL] [Abstract][Full Text] [Related]
2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
[TBL] [Abstract][Full Text] [Related]
4. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
5. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.
Khorrami M; Prasanna P; Gupta A; Patil P; Velu PD; Thawani R; Corredor G; Alilou M; Bera K; Fu P; Feldman M; Velcheti V; Madabhushi A
Cancer Immunol Res; 2020 Jan; 8(1):108-119. PubMed ID: 31719058
[TBL] [Abstract][Full Text] [Related]
6. Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC.
Coroller TP; Agrawal V; Huynh E; Narayan V; Lee SW; Mak RH; Aerts HJWL
J Thorac Oncol; 2017 Mar; 12(3):467-476. PubMed ID: 27903462
[TBL] [Abstract][Full Text] [Related]
7. Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Dercle L; Fronheiser M; Lu L; Du S; Hayes W; Leung DK; Roy A; Wilkerson J; Guo P; Fojo AT; Schwartz LH; Zhao B
Clin Cancer Res; 2020 May; 26(9):2151-2162. PubMed ID: 32198149
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
[TBL] [Abstract][Full Text] [Related]
9. Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.
Gu Q; Feng Z; Liang Q; Li M; Deng J; Ma M; Wang W; Liu J; Liu P; Rong P
Eur J Radiol; 2019 Sep; 118():32-37. PubMed ID: 31439255
[TBL] [Abstract][Full Text] [Related]
10. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
11. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
12. Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G; Barabino E; Fedeli A; Ficarra G; Coco S; Russo A; Adamo V; Buemi F; Zullo L; Dono M; De Luca G; Longo L; Dal Bello MG; Tagliamento M; Alama A; Cittadini G; Pronzato P; Genova C
Cancer Res; 2021 Feb; 81(3):724-731. PubMed ID: 33148663
[TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
16. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
[TBL] [Abstract][Full Text] [Related]
17. Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.
Xu Y; Hosny A; Zeleznik R; Parmar C; Coroller T; Franco I; Mak RH; Aerts HJWL
Clin Cancer Res; 2019 Jun; 25(11):3266-3275. PubMed ID: 31010833
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
Li Y; Wang P; Xu J; Shi X; Yin T; Teng F
Oncoimmunology; 2024; 13(1):2312628. PubMed ID: 38343749
[TBL] [Abstract][Full Text] [Related]
19. Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?
de Jong EEC; Sanders KJC; Deist TM; van Elmpt W; Jochems A; van Timmeren JE; Leijenaar RTH; Degens JHRJ; Schols AMWJ; Dingemans AC; Lambin P
Eur J Cancer; 2019 Oct; 120():107-113. PubMed ID: 31514107
[TBL] [Abstract][Full Text] [Related]
20. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis.
Sun W; Jiang M; Dang J; Chang P; Yin FF
Radiat Oncol; 2018 Oct; 13(1):197. PubMed ID: 30290849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
